| HOME >> MEDICINE >> TECHNOLOGY |
Table 27: Lumigan franchise: overview 73
Table 28: Lumigan franchise: sales forecast ($m), 2008-14 74
Table 29: Alphagan franchise: overview 76
Table 30: Alphagan franchise: sales forecast ($m), 2008-14 77
Table 31: Ozurdex: overview 79
Table 32: Ozurdex: sales forecast ($m), 2008-14 80
Table 33: Latisse: overview 82
Table 34: Latisse: sales forecast ($m), 2008-14 83
Table 35: Allergan's R&D pipeline (Phase I-registration) 84
Table 36: Total Allergan revenue by business unit and product line ($m), 2002-08 85
Table 37: Exchange rates, 2009 87
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Allergan's financial performance ($m), 2002-14 7
Figure 4: Allergan prescription pharmaceutical sales ($m), 2002-14 9
Figure 5: The central role of Botox in Allergan's strategic moves 10
Figure 6: Allergan SWOT analysis 12
Figure 7: Allergan's M&A history 25
Figure 8: Current corporate structure 29
Figure 9: Allergan prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 32
Figure 10: Key product sales ($m), 2002-14 34
Figure 11: Allergan key sales growth drivers and resistors ($m), 2002-08 36
Figure 12: Allergan key sales growth drivers and resistors ($m), 2008-14 38
Figure 13: Allergan prescription pharmaceutical sales by therapy area ($m), 2002-14 40
Figure 14: Allergan prescription pharmaceutical sales by geographic region ($m), 2002-14 43
Figure 15: Allergan launch/core/expiry configuration ($m), 2008-14 52
Figure 16: Allergan prescription pharmaceutical sales by molecule type ($m), 2002-14 53<
'/>"/>
| SOURCE Reportlinker Copyright©2009 PR Newswire. All rights reserved |